Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $588.19M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 19.64M
Average 16.28M
Returns on capital
Geron Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.0%
avg -54.2%
ROIC
-11.3%
avg -38.6%
ROA
-15.0%
avg -31.7%
Analysis
ROIC is currently the strongest return metric at -11.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | USD 1M | 59 | — | — |
Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | USD 810.55K | 59 | — | — |
Harout Semerjian | Chief Executive Officer, President & Director | USD 526.36K | 56 | 0 | <0.01% |
Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | USD 485.32K | 49 | 0 | <0.01% |
Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | USD 307.93K | 45 | 10.00K | <0.01% |
Aron Feingold | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Shannon Odam | Executive Vice President & Chief People Officer | — | 51 | — | — |
Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | — | — | — | — |
Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | — | — | — | — |
Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 13, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$19,118.70
Net Transaction Value
−$19,118.70
Net selling
Most Active
ROBERTSON MICHELLE
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Feb 18, 26Feb 18, 2026 | ROBERTSON MICHELLE Direct | Sell | $19.1K$19,118.70 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $19,118.70 over the last 12 months. That adds up to net selling of $19,118.70. ROBERTSON MICHELLE was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +575.7% | +31.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +575.7% over three years. Forward estimates point to Revenue at +31.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Geron Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GERN's management, answered from reported figures.
Who manages GERN?
Geron Corporation (GERN) lists 10 active executives. The top listed executive is Ahmed ElNawawi, Executive Vice President & Chief Commercial Officer.
Are GERN insiders buying or selling?
Recent insider activity shows net buying of $73.46M.
Continue the stock analysis
Jump to another research area for this company.